Opportunity for Targeted Protein Degradation
Many patients with non-small cell lung cancer benefit from treatment with EGFR tyrosine kinase inhibitors, or TKIs. However, patients ultimately develop resistance to EGFR TKIs, often by acquisition of a secondary resistance mutation in EGFR. A third-generation covalent EGFR inhibitor, osimertinib, can overcome this resistance mechanism and is now approved in the first-line setting.
However, acquired resistance remains an issue. Additionally, patients with the EGFR L858R mutation experience a less durable response to approved EGFR inhibitors, including osimertinib. Patients who progress after osimertinib lack effective treatment options.